Betamethasone + Neomycin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Nasal
Nasal infection
Adult: Available preparation:
Betamethasone 0.1% w/v and neomycin 0.5% w/v nasal drops

For steroid-responsive cases: Instil 2-3 drops into each nostril bid or tid.

Ophthalmic
Ocular inflammation with existing bacterial infection
Adult: Available preparation:
Betamethasone 0.1% w/v and neomycin 0.5% w/v eye drops

For steroid-responsive cases: Instil 1 or 2 drops to each affected eye up to 6 times daily according to clinical response.

Otic/Aural
Otitis externa
Adult: Available preparation:
Betamethasone 0.1% w/v and neomycin 0.5% w/v ear drops

For steroid-responsive cases where prophylactic antibiotic treatment is also required: Instil 2-3 drops into the ear 3-4 times daily. Dosage recommendations may vary among countries and individual products (refer to specific product guidelines).

Topical/Cutaneous
Corticosteroid-responsive dermatoses with secondary infection
Adult: Available preparations:
Betamethasone 1 mg and neomycin 5 mg per g of cream
Betamethasone 1 mg and neomycin 5 mg per g of ointment

As cream or ointment: Apply a small quantity onto the affected area bid or tid, or as directed. Once improvement occurs, maintain by applying once daily or even less often. Treatment must not be continued for more than 7 days, unless instructed otherwise.
Child: ≥2 years Same as adult dose. Limit treatment to 5 days.
Nhóm bệnh nhân đặc biệt
Pharmacogenomics:

Neomycin

Current studies suggest, individuals with mitochondrial deoxyribonucleic acid (DNA) mutations in the 12S ribosomal ribonucleic acid (RNA), particularly the m.1555A>G mutation, are at an increased risk of aminoglycoside-associated ototoxicity including those who had aminoglycoside serum levels within the recommended range. The m.1555A>G mutation is the most common mutation and occurs in families with maternally transmitted deafness. Although mitochondrial mutations are rare, and penetrance is uncertain, genetic testing may be considered before starting recurrent or long-term treatment with aminoglycoside antibiotics, but testing must not delay urgently needed treatment.

Additionally, studies show that patients who carry the 1555G allele may have a greater risk of aminoglycoside-induced hearing loss as compared to those patients with 1555A allele, although other genetic and clinical factors may increase this risk.
Suy thận
Topical:
Dose reduction may be required.
Chống chỉ định
Hypersensitivity. Topical: Acne vulgaris, perianal and genital pruritus, perioral dermatitis, rosacea, primary cutaneous viral infections (e.g. chickenpox, herpes simplex); primary infected skin lesions caused by fungi or bacteria, primary or secondary infections due to yeast, secondary infections due to Pseudomonas or Proteus species; otitis externa (when the ear drum is perforated). Children <2 years. Prolonged use over a large area or in large quantities in circumstances where significant systemic absorption may occur. Eye, nose, and ear drops: Viral, fungal, tuberculous or purulent conditions of the eye; fungal infections of ear or nose; presence of glaucoma or possible herpetic keratitis (e.g. dendritic ulcer); perforated tympanic membrane.
Thận trọng
Patient with psoriasis. Withdraw use when there is a spread of infection. Avoid prolonged application on the face. Eye, nose, and ear drops: Patient with known m.1555A>G mitochondrial mutations, disease-causing thinning of eye layers, family history of increased eye pressure or ototoxicity, previous eye or nose surgery. Renal impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Adrenal suppression with or without clinical features of Cushing's syndrome (particularly in children or during prolonged use), increased risk of contact sensitisation (extended or recurrent application), local hypersensitivity reaction, atrophic changes in the skin (e.g. thinning, striae, dilatation of superficial blood vessels), ototoxicity, nephrotoxicity; visual disturbance (ophthalmic); growth retardation (nasal). Rarely, generalised pustular psoriasis.
Ear and labyrinth disorders: Burning or stinging of the ear (otic).
Eye disorders: Ophthalmic: Corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity, visual field defect, mydriasis, ptosis, glaucoma, epithelial punctate keratitis; posterior subcapsular cataracts (intensive or prolonged use).
Gastrointestinal disorders: Nasal: Nausea, disturbance to sense of taste.
Nervous system disorders: Nasal: Headache, lightheadedness.
Respiratory, thoracic and mediastinal disorders: Nasal: Sneezing, epistaxis, rebound congestion, nasal irritation and dryness, bronchial asthma, perforation or ulceration of nasal septum, parosmia, anosmia.
Skin and subcutaneous tissue disorders: Local skin burning, pruritus, allergic contact dermatitis, hypertrichosis, changes in pigmentation.
Thông tin tư vấn bệnh nhân
Topical: Avoid smoking or going near naked flames after application due to the risk of severe burns. Wash fabrics (e.g. clothing, bedding, dressings) that has been in contact with this drug to reduce product build-up. Eye drops: This drug may cause transient blurred vision, if affected, do not drive or operate machinery. Remove contact lenses before administration and for a time following use.
Chỉ số theo dõi
Monitor growth in children.
Tương tác
Betamethasone: May increase the risk of systemic side effects with CYP3A4 inhibitors (e.g. ritonavir, itraconazole, cobicistat-containing products).
Neomycin: May enhance and prolong the respiratory depressant effects of neuromuscular blocking agents.
Tác dụng
Description: Betamethasone, a topical corticosteroid, has anti-inflammatory, antiallergic, and antipruritic activity. It produces its anti-inflammatory effect via multiple mechanisms to inhibit late phase allergic reactions including reduction of the density of mast cells, chemotaxis and activation of eosinophils, cytokine production, and inhibition of arachidonic acid metabolism.
Neomycin, a broad-spectrum aminoglycoside antibacterial, is effective against majority of bacteria commonly associated with skin infections. It acts by binding to 30S ribosomal subunits thus interfering with the bacterial protein synthesis.
Pharmacokinetics:
Absorption: Betamethasone: May be absorbed from normal intact skin.
Neomycin: Absorbed from wounds and inflamed skin.
Distribution: Betamethasone: Crosses the placenta (topical).
Neomycin: Distributed to tissues and concentrated in renal cortex.
Metabolism: Betamethasone: Metabolised mainly by the liver.
Excretion: Via the kidneys.
Neomycin: Half-life: 2-3 hours.
Đặc tính

Chemical Structure Image
Betamethasone

Source: National Center for Biotechnology Information. PubChem Database. Betamethasone, CID=9782, https://pubchem.ncbi.nlm.nih.gov/compound/Betamethasone (accessed on Jan. 21, 2020)


Chemical Structure Image
Neomycin

Source: National Center for Biotechnology Information. PubChem Database. Neomycin, CID=8378, https://pubchem.ncbi.nlm.nih.gov/compound/Neomycin (accessed on Jan. 21, 2020)

Bảo quản
Cream or ointment: Store below 30°C. Eye, nose, and ear drops: Store below 25°C. Protect from light and heat.
Phân loại MIMS
Thuốc khử trùng tai có corticoid / Thuốc khử trùng mắt có corticoid / Thuốc chống sung huyết mũi & các chế phẩm khác dùng cho mũi / Thuốc kháng khuẩn có corticoid dùng tại chỗ
Phân loại ATC
S01CA05 - betamethasone and antiinfectives ; Belongs to the class of corticosteroids in combination with antiinfectives. Used in the treatment of eye diseases.
D07CC01 - betamethasone and antibiotics ; Belongs to the class of potent (group III) corticosteroids, in combination with antibiotics. Used in the treatment of dermatological diseases.
S03CA06 - betamethasone and antiinfectives ; Belongs to the class of combinations of corticosteroids and antiinfectives used in ophthalmologic and otologic preparations.
Tài liệu tham khảo
Estivill X, Govea N, Barceló A et al. Familial Progressive Sensorineural Deafness Is Mainly Due to the mtDNA A1555G Mutation and Is Enhanced by Treatment with Aminoglycosides. The American Journal of Human Genetics. 1998;62(1):27-35. doi: 10.1086/301676. Accessed 02/07/2021

Gao Z, Chen Y, Guan MX. Mitochondrial DNA Mutations Associated with Aminoglycoside-Induced Ototoxicity. Journal of Otology. 2017;12(1):1-8. doi: 10.1016/j.joto.2017.02.001. Accessed 02/07/2021

Göpel W, Berkowski S, Preuss M et al. Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. BMC Pediatrics. 2014;14(1):210. doi: 10.1186/1471-2431-14-210. Accessed 02/07/2021

Aminoglycosides (Gentamicin, Amikacin, Tobramycin, and Neomycin): Increased Risk of Deafness in Patients with Mitochondrial Mutations. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. Accessed 02/07/2021.

Anon. Betamethasone (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/07/2021.

Anon. Betamethasone and Neomycin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/07/2021.

Anon. Neomycin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/07/2021.

Betacin Eye/Ear Drops (Duopharma [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 01/07/2021.

Betamethasone Valerate/Neomycin Sulphate 1 mg/5 mg/g Cream (Chemidex Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 01/07/2021.

Betamethasone Valerate/Neomycin Sulphate 1 mg/5 mg/g Ointment (Chemidex Pharma Limited). MHRA. https://products.mhra.gov.uk. Accessed 01/07/2021.

Betnesol-N Eye, Ear and Nose Drops (RPH Pharmaceuticals, AB). MHRA. https://products.mhra.gov.uk. Accessed 01/07/2021.

Betnovate-N Cream (GlaxoSmithKline Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 01/07/2021.

Betnovate-N Cream (GlaxoSmithKline Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 01/07/2021.

Buckingham R (ed). Betamethasone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/07/2021.

Buckingham R (ed). Neomycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/07/2021.

Clinical Annotation for rs267606617 (MT-RNR1); Amikacin, Aminoglycoside Antibacterials, Gentamicin, Kanamycin, Neomycin, Streptomycin or Tobramycin; Ototoxicity. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org. Accessed 02/07/2021.

Joint Formulary Committee. Betamethasone with Neomycin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/07/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Betamethasone + Neomycin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Betaderm Neomycin
  • Celestoderm-V
  • Dermasole N
  • Etbute
  • Glomazin Neo
  • Mekoderm-Neomycin
  • Mibeonate
  • Mibeonate-N
  • Neo-Besone
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in